Cancer Genetics is a center of excellence for oncology-focused clinical trials.
Posted on: Friday, May 29th, 2015
Narasimha Marella, Ph.D., Corporate Development Manager speaks about how Cancer Genetics can help biopharma companies overcome oncology-focused clinical trial challenges.
The current challenge that is faced by biotech and biopharmas that are involved in oncology drug development is their ability to accurately stratify and randomize patients for their clinical trials based on biomarkers.
Despite the tremendous amount of investment that goes into oncology clinical trials unfortunately they tend to have one of the lowest approval rates. Our solution to these problems is a CGI Select One program.
CGI delivers accurate, reliable and comprehensive biomarker assessment for patient stratification and randomization purposes. By levagering our state-of-the-art reference laboratories CGI can deliver unique genomic information that is useful for patient selection.
CGI has developed a number of proprietary assays in hematological as well as in solid tumors. The strength in our Select One program lays in the ability to offer disease focused suite of proprietary and non-proprietary tests that deliver diagnostic, prognostic, and theranostic value.
CGI is perfectly positioned to be a one-stop solution and a unique partner for all your oncology-focused clinical trials.